However clinical effect may be linked to the biological profile of the tumor since two patients, who presented with NSCLC and GIST and achieved SD, had tumors harboring BRAF G469A and PDGFRAD842V exon 18 mutations, respectively. This evidence concerns the gene BRAF and neoplasm.